POY_1170x120_8-12-19

Paul Bisaro

Amneal and Impax create diversified pharmaceutical company

Amneal and Impax create diversified pharmaceutical company

BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise. Shares of Impax  ceased trading

Allergan COO to become Amneal CEO

Allergan COO to become Amneal CEO

NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will

Amneal, Impax agree to merge

Amneal, Impax agree to merge

NEW YORK — Amneal Pharmaceuticals LLC and Impax Laboratories Inc. plan to merge in an all-stock transaction. An Amneal-Impax merger would create the fifth-largest generics supplier by gross revenue in the United States. To be named Amneal Pharmaceuticals Inc., the new entity will also possess a growing, high-margin specialty drug franchise. Financial terms of the deal